GIP

Handbook of Biologically Active Peptides

Volumn , Issue , 2013, Pages 1227-1235

  Irwin, Nigel ^a   Flatt, Peter R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884956327     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-385095-9.00166-4     Document Type: Chapter

References (34)

1. Alaña I., Malthouse J.P., O'Harte F.P., Hewage C.M. The bioactive conformation of glucose-dependent insulinotropic polypeptide by NMR and CD spectroscopy. Proteins 2007, 68:92-99.
2. Almind K., Ambye L., Urhammer S.A., Hansen T., Echwald S.M., Holst J.J., et al. Discovery of amino acid variants in the human glucose-dependent insulinotropic polypeptide (GIP) receptor: the impact on the pancreatic beta cell responses and functional expression studies in Chinese hamster fibroblast cells. Diabetologia 1998, 41:1194-1198.
3. Brown J.C., Dryburgh J.R. A gastric inhibitory polypeptide. II. The complete amino acid sequence. Can J Biochem 1971, 49:867-872.
4. de Herder W.W., Hofland L.J., Usdin T.B., de Jong F.H., Uitterlinden P., van Koetsveld P., et al. Food-dependent Cushing's syndrome resulting from abundant expression of gastric inhibitory polypeptide receptors in adrenal adenoma cells. J Clin Endocrinol Metab 1996, 81:3168-3172.
5. Dupre J., Ross S.A., Watson D., Brown J.C. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 1973, 37:826-828.
6. Ebert R., Unger H., Creutzfeldt W. Preservation of incretin activity after removal of gastric inhibitory polypeptide (GIP) from rat gut extracts by immunoadsorption. Diabetologia 1983, 24:449-454.
7. Ehses J.A., Pelech S.L., Pederson R.A., McIntosh C.H. Glucose-dependent insulinotropic polypeptide activates the Raf-Mek1/2-ERK1/2 module via a cyclic AMP/cAMP-dependent protein kinase/Rap1-mediated pathway. J Biol Chem 2002, 277:37088-37097.
8. Ehses J.A., Casilla V.R., Doty T., Pospisilik J.A., Winter K.D., Demuth H.U., et al. Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. Endocrinology 2003, 144:4433-4445.
9. Gault V.A., O'Harte F.P., Flatt P.R. Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?. Neuropeptides 2003, 37:253-263.
10. Gault V.A., Porter D.W., Irwin N., Flatt P.R. Comparison of sub-chronic metabolic effects of stable forms of naturally occurring GIP(1-30) and GIP(1-42) in high-fat fed mice. J Endocrinol 2011, 208:265-271.
11. Gault V.A., Kerr B.D., Harriott P., Flatt P.R. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with type 2 diabetes and obesity. Clin Sci (Lond) 2011, 121:107-117.
12. Gelling R.W., Wheeler M.B., Xue J., Gyomorey S., Nian C., Pederson R.A., et al. Localization of the domains involved in ligand binding and activation of the glucose-dependent insulinotropic polypeptide receptor. Endocrinology 1997, 138:2640-2643.
13. Hinke S.A., Manhart S., Speck M., Pederson R.A., Demuth H.U., McIntosh C.H. In depth analysis of the N-terminal bioactive domain of gastric inhibitory polypeptide. Life Sci 2004, 75:1857-1870.
14. Inagaki N., Seino Y., Takeda J., Yano H., Yamada Y., Bell G.I., et al. Gastric inhibitory polypeptide: structure and chromosomal localization of the human gene. Mol Endocrinol 1989, 3:1014-1021.
15. Irwin D.M., Zhang T. Evolution of the vertebrate glucose-dependent insulinotropic polypeptide (GIP) gene. Comp Biochem Physiol Part D Genomics Proteomics 2006, 1:385-395.
16. Irwin N., Gault V., Flatt P.R. Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease?. Expert Opin Investig Drugs 2010, 19:1039-1048.
17. Irwin N., Francis J.M., Flatt P.R. Alterations of glucose-dependent insulinotropic polypeptide (GIP) during cold acclimation. Regul Pept 2011, 167:91-96.
18. Jörnvall H., Carlquist M., Kwauk S., Otte S.C., McIntosh C.H., Brown J.C., et al. Amino acid sequence and heterogeneity of gastric inhibitory polypeptide (GIP). FEBS Lett 1981, 123:205-210.
19. Kubota A., Yamada Y., Yasuda K., Someya Y., Ihara Y., Kagimoto S., et al. Gastric inhibitory polypeptide activates MAP kinase through the wortmannin-sensitive and -insensitive pathways. Biochem Biophys Res Commun 1997, 235:171-175.
20. Lund P.K. The discovery of glucagon-like peptide 1. Regul Pept 2005, 128:93-96.
21. McIntosh C.H., Widenmaier S., Kim S.J. Glucose-dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide; GIP). Vitam Horm 2009, 80:409-471.
22. Meier J.J., Nauck M.A. GIP as a potential therapeutic agent?. Horm Metab Res 2004, 36:859-866.
23. Messenger B., Clifford M.N., Morgan L.M. Glucose-dependent insulinotropic polypeptide and insulin-like immunoreactivity in saliva following sham-fed and swallowed meals. J Endocrinol 2003, 177:407-412.
24. Mortensen K., Christensen L.L., Holst J.J., Orskov C. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept 2003, 114:189-196.
25. Nauck M.A., Bartels E., Orskov C., Ebert R., Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993, 76:912-917.
26. Nauck M.A., Heimesaat M.M., Orskov C., Holst J.J., Ebert R., Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993, 91:301-307.
27. Parthier C., Kleinschmidt M., Neumann P., Rudolph R., Manhart S., Schlenzig D., et al. Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor. Proc Natl Acad Sci U S A 2007, 104:13942-13947.
28. Polak J.A., Bloom S.R. Localization of regulatory peptides in the gut. Brit Med Bull 1982, 38:303-307.
29. Seino S., Shibasaki T. PKA-dependent and PKA-independent pathways for cAMP-regulated exocytosis. Physiol Rev 2005, 85:1303-1342.
30. Straub S.G., Sharp G.W.G. A wortmannin-sensitive signal transduction pathway is involved in the stimulation of insulin release by vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide. J Biol Chem 1996, 271:1660-1668.
31. Takeda J., Seino Y., Tanaka K., Fukumoto H., Kayano T., Takahashi H., et al. Sequence of an intestinal cDNA encoding human gastric inhibitory polypeptide precursor. Proc Natl Acad Sci USA 1987, 84:7005-7008.
32. Ugleholdt R., Poulsen M.L., Holst P.J., Irminger J.C., Orskov C., Pedersen J., et al. Prohormone convertase 1/3 is essential for processing of the glucose-dependent insulinotropic polypeptide precursor. J Biol Chem 2006, 28:11050-11057.
33. Unger R.H., Eisentraut A.M. Entero-insular axis. Arch Intern Med 1969, 123:261-266.
34. Usdin T.B., Mezey E., Button D.C., Brownstein M.J., Bonner T.I. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinol 1993, 133:2861-2870.